Lenz Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Lenz Therapeutics Inc 's ROA in the second quarter of 2026?
Lenz Therapeutics Inc recorded a cumulative net loss of $-126 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -49.11%.

However, within the Healthcare sector 559 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3840, from total ROA ranking in the first quarter of 2026 at 4361.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	9.16 %	35.42 %	42.07 %	-5.94 %	7.85 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-126	-109	-82	-59	-52
Return On Assets (TTM)	-49.11 %	-43.32 %	-35.13 %	-27.89 %	-24.43 %
LENZ's Total Ranking	# 3840	# 4361	# 3715	# 3671	# 3683
Total Assets (TTM) in million	237	273	306	211	217
Seq. Total Assets Change	-12.95 %	-10.9 %	45.17 %	-3.05 %	7.99 %
Seq. Net Income Change	-	-	-	-	-

LENZ's 5 Years Annual ROA >> Back to LENZ Management Effectiveness >> Compare LENZ ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 78
Sector	# 560
Overall	# 3883

Return On Assets Statistics
High	Average	Low
-22.65 %	-30.64 %	-49.14 %
(Mar 31 2025)		(Jun 30 2026)

Financial Statements
Lenz Therapeutics Inc 's Assets	$ 237 million	LENZ's Balance sheet
Lenz Therapeutics Inc 's Income	$ -32 million	Quarterly LENZ's Income Statement
LENZ's Income by Division		See LENZ's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	42.07 %	14.25 %	-40.61 %	-18.9 %	-
Total Assets in million	306	215	188	317	391
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-82	-50	-125	-101	0
Annual Return On Assets	-26.85 %	-23.12 %	-66.14 %	-31.85 %	0 %

LENZ's 5 Years Annual ROA >> Back to LENZ Management Effectiveness >> Compare LENZ ROA to its Competitors

More Return On Assets Ratios
LENZ's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
LENZ's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for LENZ's Competitors
Subscribers only: Roa for Lenz Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for LENZ's Customers

You may also want to know
LENZ's Roi	LENZ's Inventory Turnover Ratio	LENZ's Growth Rates	LENZ's Dividend Comparisons
	LENZ's Profitability Ratios	LENZ's Asset Turnover Ratio	LENZ's Dividend Growth
LENZ's Roe	LENZ's Valuation Ratios	LENZ's Financial Strength Ratios	LENZ's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:40:00+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.